Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Inclusion Criteria: * Cytologically or pathologically confirmed gallbladder carcinoma or cholangiocarcinoma * No ampullary carcinoma * Locally advanced unresectable or distant metastatic disease * Measurable disease * Patients with biliary obstruction must have decompression of the biliary tree by ERCP and stenting or percutaneous drainage * No prior systemic treatment for metastatic or unresectable locally advanced disease * No known brain metastases * Zubrod performance status of 0-1 * Leukocyte count ≥ 3,000/mm\^3 * ANC ≥ 1,000/mm\^3 * Platelet count ≥100,000/mm\^3 * Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN) * For patient who had decompression of the biliary tree within the past 14 days, stability of the bilirubin level needs to be confirmed with two measurements within 5 to 7 days of each other * Serum albumin ≥ 2.5 g/dL * AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for liver metastases) * Creatinine clearance ≥ 60 mL/min * Not pregnant or nursing * Fertile patients must agree to use effective contraception * No active biliary sepsis * No bleeding diathesis * No uncontrolled or clinically significant cardiovascular disease, including any of the following: * Myocardial infarction within the past 6 months * Uncontrolled angina within the past 6 months * NYHA class II-IV congestive heart failure * Grade 3 cardiac valve dysfunction * Cardiac arrhythmia not controlled by medication * History of stroke or transient ischemic attack within t…